Royalty Pharma plc (RPRX) Bank of America Global Healthcare Conference 2026 September 23, 2026 6:45 AM EDT
Company Participants
Terrance Coyne – Executive VP & CFO
Conference Call Participants
Richard Wagner – BofA Securities, Research Division
Presentation
Richard Wagner
BofA Securities, Research Division
Good morning. My name is Richard Wagner. I work with Jason Gerberry covering U.S. large cap pharma based in London. On his behalf, I’m pleased to welcome Terry Coyne, CFO of Royalty Pharma and Greg Butz and Managing and Partnering for a 40-minute fireside chat. So thank you both.
Terrance Coyne
Executive VP & CFO
Thanks for having us.
Richard Wagner
BofA Securities, Research Division
My pleasure. So if we could start with pharma policy, what are you paying close attention to ahead of the midterm elections, how would be impactful biopharma ecosystem.
Question-and-Answer Session
Terrance Coyne
Executive VP & CFO
Yes. So it’s a great question. I think there’s a lot of moving pieces on the policy front. And I wouldn’t point to anything — any one thing in particular. Obviously, MFA continues to come up. But I think we’re paying attention to sort of the broad better coming out of [indiscernible] and has any strong views one way or another on how this all shaked out, but we’re definitely paying close attention.
Richard Wagner
BofA Securities, Research Division
You mentioned in — this question is from the OUS impact. So there was a publication in The Lancet that argued that biopharma was under pressure to increase U.S. launch prices, but potentially forego commercialization in certain EU countries. So in the past, Royalty framed the OUS impacts from MFN, TBD. Are these dynamics becoming clearer, one? And then second, are they factoring into your…
Terrance Coyne
Executive VP & CFO
So I would still say it’s largely
